J&J's Janssen teams up with Intrexon for diabetes pill

Platform specialist Intrexon ($XON) has teamed up with Johnson & Johnson's ($JNJ) Janssen for a research collaboration to use its oral delivery system in therapies designed to treat Type 2 diabetes, obesity or metabolic disorders. The terms of the deal remain undisclosed.

Intrexon touts its ActoBiotics platform as one that can take on multiple aspects of Type 2 diabetes in a single pill and maintain glycemic control in the long term.

The pill delivers proteins and peptides to the oral and gastrointestinal tract using food-grade microbes called Lactococcus lactis engineered to contain the ActoBiotics drugs.

"I am very pleased we are partnering with Janssen to address Type 2 diabetes and related conditions," Intrexon Senior Vice President Samuel Broder said in a statement. "Through the use of Intrexon's proprietary ActoBiotics platform, we believe this collaboration will make a significant contribution to this substantial global health issue. The breadth of opportunity to treat an array of diseases with our versatile ActoBiotics technology continues to expand."

- here's the release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.